Figure 2: Assessment of mortality and neurological deficiency in CEGI-treated MCAO rats. (A) The mortality remained unchanged among each group on day 14 after surgery. (B–D) Modified Bederson score, beam balance test and rotameric test at 3, 7 and 14 days post-MCAO. Data are presented as the mean ± SEM (n = 9 per group at each time point). *P < 0.05, vs. MCAO group (Kruskal-Wallis one-way analysis of variance followed by Dunn's post hoc test). CEGI: Cattle encephalon glycoside and ignotin; GM-1: monosialotetrahexosyl ganglioside; MCAO: middle cerebral artery occlusion.